HERCULES, Calif — November 28, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that its board of directors has authorized a new share repurchase program, granting the Company authority to repurchase, on a discretionary basis, up to $250 million of the outstanding... Read more
HERCULES, Calif. — June 12, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex® 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of... Read more
HERCULES, Calif. — March 13, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that management intends to propose Jeffrey Edwards, Gregory Hinckley and Arnold Pinkston for election to its Board of Directors at the Company’s 2017 Annual Meeting of Stockholders. Norman... Read more
HERCULES, Calif. — January 16, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during... Read more
SAN DIEGO and HERCULES, Calif. — January 9, 2017 — Illumina, Inc. (NASDAQ: ILMN) and Bio‑Rad Laboratories, Inc. (NYSE: BIO)(NYSE: BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers... Read more